Biotech Earnings Webcasts: How to Watch and What to Track in 2026

Biotech earnings webcasts differ from standard corporate calls in one fundamental way: a single drug's sales trajectory, a Phase 3 interim readout, or a sentence about regulatory timelines can move a stock more than the headline revenue figure. Unlike consumer or industrial companies, where revenue tends to spread across many product lines, biotech firms often derive the bulk of their sales from one or two medicines. That concentration makes understanding pipeline language and franchise dynamics as important as reading the income statement.

What the Numbers Actually Tell You

The first metrics to note on any biotech call are total revenue growth, lead-drug sales concentration, and earnings per share. Regeneron Pharmaceuticals (REGN) reported Q1 2026 revenue of $3.6 billion, up 19% year over year, with non-GAAP EPS growing 15%. That combination of accelerating top-line growth alongside earnings expansion signals that scale benefits are flowing through the model.

Vertex Pharmaceuticals (VRTX) reported Q1 2026 total revenue of $2.99 billion, representing 8% growth year over year. Vertex ended the quarter with $13 billion in cash and investments and repurchased approximately $344 million in shares, giving context for how management balanced near-term capital returns against longer-term pipeline investment. Gilead Sciences (GILD) posted Q1 2026 total product sales of $6.9 billion, up 5% year over year; excluding Veklury, the COVID antiviral, the base business grew 8% to $6.8 billion, a distinction management highlighted to show underlying commercial momentum.

Reading Lead-Drug Concentration

On a REGN call, DUPIXENT dominates the discussion for good reason. DUPIXENT global net sales reached $4.9 billion in Q1 2026, up 31% on a constant currency basis, treating over 1.4 million patients worldwide. When a single drug generates that level of sales and is still growing at 31%, the key question to track is what new indications management is pursuing, because each regulatory approval adds another patient population and another growth runway.

DUPIXENT already covers atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis, among other conditions. Each new approval in the pipeline presentation represents a potential multi-hundred-million-dollar revenue stream. Tracking the Phase 3 readout calendar for a franchise drug like DUPIXENT is one of the highest-signal activities during a biotech earnings webcast.

How to Interpret Pipeline Data

Phase 3 interim results often appear in the prepared remarks section of a call, and the numbers require context to read correctly. Vertex reported that its Povitacicept therapy for IgA nephropathy, a kidney disease, showed a 52% reduction in proteinuria in Phase 3 interim data. Proteinuria is the presence of excess protein in urine and serves as an established proxy measure for kidney disease progression, so a 52% reduction represents a clinically meaningful signal.

What makes that Vertex data point particularly notable is the regulatory execution that followed. Vertex completed the regulatory submission just 27 days from database lock to filing, a timeline that reflects a fully prepared submission package. During a call, management commentary about submission timing and engagement with the FDA provides a practical indicator of how far along the regulatory process actually is.

Vertex also reported early commercial traction for two newer therapies. KASJEVY, a gene editing treatment for sickle cell disease and beta thalassemia, had over 500 patients start treatment and generated $43 million in Q1 2026 revenue. GERNAVICS, a non-opioid pain medication, contributed $29 million in the same period. Together, these two products represent Vertex's early commercial foothold beyond its established cystic fibrosis franchise.

Regeneron's pipeline section included data on cemdisiran for myasthenia gravis, a neuromuscular disease. The drug delivered a 2.3-point improvement versus placebo in Phase 3 and is dosed quarterly rather than every two weeks, which is the dosing schedule for certain competitors. Dosing convenience is a commercial differentiator that management teams typically quantify during calls, as it affects both patient adherence and market adoption trajectories.

Product Transitions and Portfolio Mid-Cycle

One of the more instructive dynamics in Q1 2026 came from Regeneron's ophthalmology portfolio. EYLEA HD, the higher-dose formulation, posted U.S. sales of $468 million in Q1 2026, up 52% year over year. At the same time, original EYLEA declined 36%. That pattern of a successor drug growing rapidly while the legacy version contracts is a normal mid-cycle transition, not a sign of commercial distress.

When tracking portfolio transitions, the relevant question is whether the successor drug is capturing patients who switch away from the legacy product or is also attracting new patients. If total franchise volume is growing, the transition is working. If total volume is flat while market mix shifts, it signals the company is cannibalizing its own revenue rather than expanding the overall addressable market. Management often addresses this distinction directly in response to analyst questions during the Q&A portion of the call.

M&A Announcements on the Call

Gilead Sciences made the largest M&A disclosure of the Q1 2026 earnings season among these companies, closing three acquisitions totaling approximately $11.5 billion in upfront costs. The deals covered Arcellx for anitocel, a CAR-T therapy for multiple myeloma; Tubulis for antibody-drug conjugate technology; and Oral Medicines for autoimmune indications. When an acquisition announcement appears during a webcast, the key details to note are the therapeutic area, the development stage of the lead asset, and whether management discloses expected near-term revenue contribution.

Gilead's underlying commercial business provides the context for why that level of acquisition activity is financially sustainable. Biktarvy holds over 52% U.S. market share in HIV treatment and generated $3.4 billion in Q1 2026. The HIV prevention drug lenacapavir, marketed as Yes2Go, posted quarterly sales of $166 million, up 72% from the prior quarter, with management expecting the drug to reach $1 billion in sales in its first full year. A stable, high-margin franchise generating that level of cash flow creates capacity for large-scale pipeline investment through acquisitions.

What to Have Open During a Webcast

A structured approach to any biotech earnings call starts with four materials open simultaneously: the company's investor relations page, the press release (which carries the income statement and product-level sales table), the slide deck (which typically includes pipeline status charts and full-year guidance), and a prepared audio summary for each company covering the key data points.

• Investor relations page: the source for the press release, slide deck, and webcast replay link
• Press release: product-level revenue table, earnings per share, and full-year guidance ranges
• Pipeline slide: Phase 3 status, expected data readout dates, and indication expansion plans
• Q&A section: management responses to analyst questions often contain more granular detail than the prepared remarks
• Beta Finch episode for each company: a structured audio summary of the key numbers and management commentary

The Q1 2026 webcasts from Regeneron, Vertex, and Gilead each illustrated a different dimension of what makes biotech earnings calls information-dense. REGN demonstrated franchise drug momentum at scale, with DUPIXENT's $4.9 billion quarter anchoring the entire revenue story. VRTX showed how pipeline execution translates into regulatory velocity, with the Povitacicept submission timeline as a concrete example. GILD illustrated how a stable HIV franchise, anchored by Biktarvy's 52% U.S. market share, supports an aggressive M&A strategy at scale. The Beta Finch Regeneron Q1 2026 earnings breakdown, Vertex Pharmaceuticals Q1 2026 analysis, and Gilead Sciences Q1 2026 episode each provide structured audio walkthroughs of the numbers and management commentary from those calls.